Citable company snapshot
Bio-Techne's latest SEC-sourced 2026-06-30 period shows $321.19M in revenue and $54.60M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue (computed) | Jun 30, 2026 | $321.19M | $311.42M | +3.1% |
| Gross Profit (computed) | Jun 30, 2026 | $211.39M | $208.29M | +1.5% |
| Operating Income (computed) | Jun 30, 2026 | $74.28M | $75.50M | -1.6% |
| Net Income (computed) | Jun 30, 2026 | $54.60M | $51.05M | +7.0% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $95.42M | $86.66M | +10.1% |
| Free Cash Flow (computed) | Jun 30, 2026 | $86.94M | $77.58M | +12.1% |
Source: SEC EDGAR financial statements (derived); period Jun 30, 2026; filed Aug 24, 2026; accession 0001104659-26-100322.
TECH company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.